Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has
undergone rapid changes with innovations in oncogene-directed therapy and immune …

Objective To explore the clinicopathological impact of lncRNAs, immunotherapy, and DNA
methylation in lung squamous cell carcinoma (LUSC), emphasizing their exact roles in …

Background The frequency of epidermal growth factor receptor (EGFR) mutations and the
efficacy of tyrosine kinase inhibitor (TKI) in Chinese female patients with lung squamous cell …

Background Metastatic epidermal growth factor receptor-mutated (EGFR+) non-small-cell
lung cancer (NSCLC) can present de novo or following previous nonmetastatic disease …

Abstract Background N 6-methyladenine (m 6 A) is the most common modification of mRNA
and IncRNA in higher organisms. m 6 A has been confirmed to be related to the formation …

An observational study to evaluate factors predicting survival in patients of non-small cell lung
cancer with poor performance status in resource-constrained settings - PMC Back to Top Skip …

The discovery of mutations in the epidermal growth factor receptor (EGFR) mutations in
metastatic nonsmall cell lung cancer (NSCLC) has been a focal point in changing the …

Afatinib is an ErbB family blocker approved for the treatment of epidermal growth factor
receptor mutation‐positive nonsmall‐cell lung cancer. A pivotal trial demonstrated significant …

CD109 is a surface antigen of cells, which is highly expressed in several types of human
cancers including various squamous cell carcinomas and adenocarcinomas. CD109 …